Ruxolitinib and Decitabine for High Risk Hematological Malignancies

Inclusion Criteria

• •1. Relapsed/refractory acute leukemia with indications for allogeneic hematopoietic stem cell transplantation; High risk acute leukemia with indications for allogeneic hematopoietic stem cell transplantation;
• •2. Medium to high risk myelodysplastic syndrome, myeloproliferative disease, myelodysplastic syndrome/myeloproliferative disease, Chronic myelomonocytic leukemia;
• •3. Have matched sibling donors, ≥8/10 HLA matched unrelated donors or haploidentical donors
• •4. All patients should aged 12 to 65 years;
• •5. Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;
• •6. Renal function: creatinine ≤the upper limit of normal;
• •7. Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness;
• •8. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
• •9. Have signed informed consent.